Re­mem­ber that mega-block­buster val­u­a­tion Ab­b­Vie as­signed to Ro­va-T? It’s start­ing to van­ish — qui­et­ly

Ab­b­Vie ex­ecs have fi­nal­ly got­ten around to do­ing what a host of an­a­lysts man­aged to ac­com­plish long ago: writ­ing down the val­ue of their once much-vaunt­ed can­cer drug Ro­va-T.

Way down.

On Fri­day the com­pa­ny filed a no­tice with the SEC ex­plain­ing that Ab­b­Vie $AB­BV has de­cid­ed to knock $4 bil­lion off the book val­ue of the drug weeks af­ter re­searchers were forced to stop re­cruit­ing pa­tients in the now in­fa­mous TAHOE study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.